Jörg Fischer

Title: Jörg Fischer: Innovator in Oral Dosage Forms and Probiotic Treatments

Introduction

Jörg Fischer is a notable inventor based in Brakel, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms and probiotic treatments. With a total of 2 patents, Fischer's work has the potential to impact the way active substances are delivered in medical applications.

Latest Patents

Fischer's latest patents include an innovative oral dosage form designed to deliver active substances to the oral cavity. This invention focuses on a mucoadhesive active composition and a corresponding mucoadhesive dosage form, specifically an orodispersible tablet that can effectively deliver probiotic substances. Additionally, he has developed a method for producing this composition and processing it into a mucoadhesive dosage form. Another significant patent relates to a novel bacterial strain, GOS 42 (DSM 32131), which has been isolated for its potential use in treating and preventing inflammation.

Career Highlights

Throughout his career, Jörg Fischer has worked with prominent companies such as Symrise AG and Probi AB. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to the development of effective medical solutions.

Collaborations

Fischer has collaborated with notable colleagues, including Marcus Rudolf Götz and Rolf Daniels. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented inventions.

Conclusion

Jörg Fischer's contributions to the field of pharmaceuticals, particularly in oral dosage forms and probiotic treatments, highlight his innovative spirit and dedication to improving medical solutions. His patents reflect a commitment to advancing healthcare through effective drug delivery systems.